Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.89 |
| ▸ | APP | P05067 | 3/20 | 0.89 |
| ▸ | BACE1 | P56817 | 12/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.77 |
| ▸ | MAOA | P21397 | 2/20 | 0.77 |
| ▸ | MAOB | P27338 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | PTGES | O14684 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599057 | 1.00 | MAPT (0.89) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL14259639 | 0.95 | MAPT (0.86) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3222158 | 0.94 | APP (1.00) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3221529 | 0.94 | BACE1 (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL1645393 | 0.94 | MAPT (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3211827 | 0.94 | MAPT (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3222140 | 0.94 | APP (1.00) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL1645395 | 0.94 | MAPT (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3211814 | 0.94 | MAPT (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 | |
| SCHEMBL3221512 | 0.94 | BACE1 (0.80) | MAPTAPPBACE1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025023364-A1 | DRUG-ENZYME COMPLEX OF CURCUMIN DERIVATIVE AND PROTEASE AND USE THEREOF | 주식회사 앤씨비아이티 | 2025-01-30 | — | — | WO | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20140161827-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012154809-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-11-15 | — | — | WO | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | MAPT 448/4885APP 662/4885BACE1 750/4885 |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | MAPT 2526/4885APP 3745/4885BACE1 2224/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | MAPT 448/4885APP 662/4885BACE1 750/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | MAPT 2526/4885APP 3745/4885BACE1 2224/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | MAPT 448/4885APP 662/4885BACE1 750/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | MAPT 2526/4885APP 3745/4885BACE1 2224/4885 |
| US-20140161827-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BAX, ERBB2, BCL2 | MAPT 2734/4885APP 1636/4885BACE1 773/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | MAPT 2066/4885APP 3170/4885BACE1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.